Diabetes
-
Prescribing summary cardOzempic® ▼ (semaglutide) 1.34 mg/ml once‑weekly GLP-1 RA
Commissioned by Novo Nordisk Limited
-
Independent professional body guideline
Type 2 diabetes treatment pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
-
Independent professional body guideline
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
-
Guidance card
AWMSG card: Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼)
Funded by Novo Nordisk Limited
-
Guidance card
Semaglutide 0.25 mg, 0.5 mg and 1 mg solution for injection in pre-filled pen (Ozempic®▼) SMC No. (2092)
Funded by Novo Nordisk Limited
-
NICE guideline
NICE pancreatitis guideline
Summary of NICE guidance on pancreatitis covers managing complications, nutrition support, and referral for specialist treatment.
-
Supplement
Type 2 diabetes: an overview of the SIGN guideline on pharmacological management of glycaemic control
Production of this Guidelines supplement has been funded by an educational grant from Napp Pharmaceuticals Limited. The grant included an honorarium for the author. Napp Pharmaceuticals Limited has reviewed the supplement for technical accuracy and to ensure compliance with regulations. Napp
-
Working party guideline/algorithm
Pancreatic exocrine insufficiency guideline
This management algorithm was developed by a multidisciplinary expert panel: Hambling C et al with the support of a grant from Mylan Ltd.
-
SIGN guideline
SIGN type 2 diabetes guideline
This summary provides key recommendations on lifestyle management, treatment options, diabetic CVD, and CKD. Includes a useful treatment algorithm
-
Test and reflect
NICE guideline on diabetes footcare
This CPD activity consists of 8 multiple-choice questions designed to test your knowledge on the management of diabetic foot problems
